Literature DB >> 1733383

Valvular heart disease in the primary antiphospholipid syndrome.

E Galve1, J Ordi, J Barquinero, A Evangelista, M Vilardell, J Soler-Soler.   

Abstract

OBJECTIVE: To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome.
DESIGN: Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 22 months.
SETTING: University-based tertiary medical center. PATIENTS: Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls.
MEASUREMENTS AND MAIN RESULTS: Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valvular involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with mitral valve involvement was 7.0 +/- 1.6 mm, compared with 2.7 +/- 0.8 mm in patients with normal valves and 3.2 +/- 0.9 mm in the control group. The mean aortic valve thickness in patients with aortic valve involvement was 3.8 +/- 0.5 mm compared with 1.4 +/- 0.3 mm in patients with normal valves and 1.4 +/- 0.5 mm in the control group. Stenotic lesions were not found. Regurgitation was severe in two patients (one required surgery), moderate in three patients, and mild in three patients.
CONCLUSIONS: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome. The lesions are left-sided, causing regurgitation that may be clinically important.

Entities:  

Mesh:

Year:  1992        PMID: 1733383     DOI: 10.7326/0003-4819-116-4-293

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

Review 1.  Worldwide perspective of valve disease.

Authors:  J Soler-Soler; E Galve
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 2.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 3.  Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.

Authors:  P Edelman; A M Rouquette
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 6.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

7.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 8.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

9.  Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies.

Authors:  Piotr Leszczyński; Ewa Straburzyńska-Migaj; Izabela Korczowska; Jan K Łacki; Stefan Mackiewicz
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

10.  M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome.

Authors:  N Coudray; D de Zuttere; O Blétry; J C Piette; B Wechsler; P Godeau; J C Pourny; Y Lecarpentier; D Chemla
Journal:  Br Heart J       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.